Impact of potassium citrate on urinary risk profile, glucose and lipid metabolism of kidney stone formers in Switzerland by Wiegand, Anna et al.
O R I G I N A L A R T I C L E
Impact of potassium citrate on urinary risk profile,
glucose and lipid metabolism of kidney stone formers
in Switzerland
Anna Wiegand1, Gioia Fischer1, Harald Seeger1,2, Daniel Fuster 2,3,
Nasser Dhayat2,3, Olivier Bonny2,4, Thomas Ernandez2,5, Min-Jeong Kim2,6,
Carsten A. Wagner 2,7 and Nilufar Mohebbi1,2
1Division of Nephrology, University Hospital of Zurich, Zurich, Switzerland, 2Swiss Kidney Stone Cohort,
National Center of Competence in Research, NCCR-Kidney, Switzerland, 3Department of Nephrology and
Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 4Service of
Nephrology, University Hospital of Lausanne, Lausanne, Switzerland, 5Service of Nephrology, University
Hospital of Geneva, Geneva, Switzerland, 6Clinic for Transplantation Immunology and Nephrology, University
Hospital Basel, Basel, Switzerland and 7Institute of Physiology, University of Zurich, Zurich, Switzerland
Correspondence and offprint requests to: Nilufar Mohebbi; E-mail: Nilufar.Mohebbi@usz.ch
ABSTRACT
Background. Hypocitraturia and hypercalciuria are the most prevalent risk factors in kidney stone formers (KSFs). Citrate
supplementation has been introduced for metaphylaxis in KSFs. However, beyond its effects on urinary parameters and
stone recurrence, only a few studies have investigated the impact of citrate on other metabolic pathways such as glucose or
lipid metabolism.
Methods. We performed an observational study using data from the Swiss Kidney Stone Cohort. Patients were subdivided
into two groups based on treatment with potassium citrate or not. The outcomes were changes of urinary risk parameters,
haemoglobin A1c (HbA1c), fasting glucose, cholesterol and body mass index (BMI).
Results. Hypocitraturia was present in 19.3% of 428 KSFs and potassium citrate was administered to 43 patients (10.0%) at a
mean dosage of 38196 1796 mg/day (corresponding to 12.565.9 mmol/ day). Treatment with potassium citrate was
associated with a significantly higher mean change in urinary citrate (P¼0.010) and urinary magnesium (P¼0.020)
compared with no potassium citrate treatment. Exogenous citrate administration had no effect on cholesterol, fasting
glucose, HbA1c and BMI. Multiple linear regression analysis demonstrated no significant association of 1,25-
dihydroxyvitamin D3 [1,25(OH)2 D3] levels with urinary citrate excretion.
Conclusion. Potassium citrate supplementation in KSFs in Switzerland resulted in a beneficial change of the urinary risk
profile by particularly increasing anti-lithogenic factors. Fasting glucose, HbA1c, cholesterol levels and BMI were unaffected
by potassium citrate therapy after 3 months, suggesting that potassium citrate is safe and not associated with unfavourable
metabolic side effects. Lastly, 1,25(OH)2 D3 levels were not associated with urinary citrate excretion.
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INTRODUCTION
Urolithiasis is common in developed countries, with a preva-
lence of 10%, and is associated with an increased risk for subse-
quent loss of kidney function [1–6] and cardiovascular disease
[7]. The recurrence rate after the first stone episode is up to 40%
in the first 5 years and 75% after 20 years [8]. The identification
of risk factors is essential for the implementation of preventive
therapy in kidney stone formers (KSFs) [9–11]. Urinary supersat-
uration of calcium oxalate or calcium phosphate has been dis-
cussed as a driving force for stone formation that consequently
results in crystallization and lithogenesis [8, 12]. Hypercalciuria
and hypocitraturia are the most important risk factors for stone
formation, followed by hyperoxaluria and hyperuricosuria [11,
13–16].
Citrate is a strong inhibitor of crystallization [17, 18] and cit-
rate supplementation has been shown to significantly increase
urinary citrate excretion and decrease stone recurrence rates in
hypocitraturic and normocitraturic KSFs [19, 20]. Citrate is ad-
ministered orally, absorbed by the small intestine and filtered
into urine, where it complexes and reduces the concentration of
free calcium ions, thereby preventing calcium supersaturation.
In addition, citrate supplementation increases urinary pH, which
in turn further promotes urinary citrate excretion and prevents
uric acid, calcium oxalate and cystine stone formation [13, 14, 18,
21]. The liver metabolizes a proportion of the orally administered
citrate to acetyl coenzyme A (acetyl-CoA), which is a precursor of
fatty acid and cholesterol synthesis. Endogenous citrate exerts a
positive regulatory effect on lipogenesis and a negative regula-
tory effect on glycolysis [22–24]. Despite the widespread use of
potassium citrate, no data are available regarding additional
effects of oral citrate supplementation on glucose or lipid metab-
olism in KSFs.
Interestingly, there is evidence that vitamin D significantly
reduces mitochondrial citrate metabolism (oxidation) in renal
cells, resulting in increased urinary citrate excretion in rats [25].
Furthermore, 1,25-dihydroxyvitamin D3 [1,25(OH)2 D3] may
modulate intracellular citrate metabolism and transport, which
consequently leads to modified citrate excretion [13, 26]. In ad-
dition, vitamin D receptor gene polymorphisms may enhance
the effects of 1,25(OH)2 D3 on citrate metabolism [27]. To date, it
is not known whether there is an association between 1,25(OH)2
D3 levels and urinary citrate excretion in KSFs.
The aim of this study was to evaluate the impact of oral po-
tassium citrate therapy on the urinary stone risk profile of KSFs
in Switzerland and its effect on glucose and lipid metabolism.
Additionally, we investigated if 1,25(OH)2 D3 levels correlate
with urinary citrate excretion.
MATERIALS ANDMETHODS
Study design and study population
We performed an observational study using prospectively col-
lected data from the Swiss Kidney Stone Cohort (SKSC) [28]. Our
study has been approved by the Cantonal Ethics Committee
Zurich and the local ethics committees of all participating
centres.
Inclusion criteria included 18 years of age, any recurrent
kidney stone former or first KSF with one or more of the follow-
ing risk factors (first presentation at <25 years of age, positive
family history, non–calcium oxalate kidney stones, gastrointes-
tinal disease, osteoporosis, nephrocalcinosis, pregnancy, single
kidney, gout, metabolic syndrome, diabetes mellitus type 1/2,
bilateral or more than one kidney stones, chronic urinary tract
infections, chronic kidney disease, kidney transplantation or
having remaining kidney stones 3 months after therapy).
Study visits were performed at baseline, after 3 months and
once annually up to 3 years according to the SKSC protocol.
Data on physical activity, medical history, medication and de-
mographic information were collected. All data were extracted
from the study database (SLims 5.4.77) at baseline and after 3
months. Patients were subdivided into two groups based on
treatment with potassium citrate (C; including potassium cit-
rate or potassium citrate/hydrogen carbonate) or not (NC). Only
citrate-naı¨ve patients were included in this study.
Laboratory analyses were performed at Bioanalytica labora-
tories. Twenty-four-hour urine collections were collected with
thymol and paraffin oil. The urinary pH value was measured
by a pH electrode. Blood samples were obtained in the morning
after an overnight fast. Stone composition was determined by
X-ray diffractometry or infrared spectroscopy. If patients had
several stones analysed, all analyses were included in the
study.
Definitions
Hypocitraturia was defined as 24-h urinary citrate excretion
<1.50, hypercalciuria as 24-h urinary calcium excretion >6.25 in
females and >7.50 in males, hyperoxaluria as 24-h urinary oxa-
late excretion >0.5 and hyperuricosuria as 24-h urinary uric
acid excretion >4.5 in females and >4.8 in males (all values in
mmoles). Pure stones were defined as >95% of a single
component.
Statistical analyses
Data are presented as mean 6 standard deviation (SD) unless
otherwise specified. Normal distribution was tested with the
Shapiro–Wilk test and normality was assumed for sample
sizes >30. Comparisons among the groups were performed us-
ing the chi-squared test and Fisher’s exact test for categorical
variables and Student’s t-test for continuous variables. For
comparisons, paired or unpaired parametric (Student’s t-test)
and non-parametric tests (signed-rank tests) were used. The
statistical significance threshold was set at P< 0.05 and all
tests were two-sided. Statistical analyses were performed us-
ing R (version 3.3.2; R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Characteristics of the study population
Patient characteristics are shown in Tables 1 and 5. A total of
428 participants were analysed, including 304 (71.0%) male sub-
jects. The mean patient age was 47.26 14.1 years. The mean
body mass index (BMI) was 26.664.7 kg/m2 and diabetes melli-
tus type 2 and type 1 were present in 43 (10.0%) and 3 (0.7%)
patients, respectively. Of the patients, 41.8% were recurrent
stone formers and stone composition was available in 37.2% of
934 reported calculi. A total of 177 (51.0%) stones were of mixed
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type, with 109 (61.6%) consisting of >50% calcium oxalate; 43.2%
were pure calcium oxalate stones followed by pure apatite
(2.6%), uric acid (2.0%) and other origins (1.2%). In the entire co-
hort, hypercalciuria was the most prevalent metabolic risk fac-
tor [113 patients (28.3%)], followed by hypocitraturia [78 patients
(19.3%)], hyperuricosuria [40 patients (10.0%)] and hyperoxaluria
[9 patients (2.2%); Figure 1].
Ten per cent of stone formers were treated with
potassium citrate
Potassium citrate was administered to 43 patients (10.0%) at
a mean dosage of 381961796 mg/day (corresponding to
12.565.9 mmol/day; Table 1). Interestingly, only 14 (32.6%) of
the 43 patients were hypocitraturic. Of the 43 citrate-treated
patients, 28 (65.1%) were male, the median BMI was
Table 1. Baseline characteristics of stone formers with potassium citrate supplementation (Group C) compared with patients without supple-
mentation (Group NC)
Variables Reference values Total NC C P-value
Patients, n (%) – 428 385 (90.0) 43 (10.0) –
Age (years) – 47.2 (14.1) 47.2 (14.1) 46.5 (14.5) 0.731
Gender (male), n % – 304 (71.0) 276 (71.7) 28 (65.1) 0.469
BMI (kg/m2) – 26.6 (4.7) 26.5 (4.7) 27.6 (4.7) 0.187
Received citrate therapy after baseline, n (%) – 43 (10.0) – – –
Medical history, n (%)
Hypertension – 83 (19.4) 69 (17.9) 14 (32.6) 0.092
Not available – 41 (9.6) 41 (10.6) 0 (0.0)
Diabetes mellitus – 0.429
Type 1 – 3 (0.7) 3 (0.8) 0 (0.0)
Type 2 – 43 (10.0) 36 (9.4) 7 (16.3)
Not available – 38 (8.9) 38 (9.9) 0 (0.0)
IBD – 20 (4.7) 18 (4.7) 2 (4.7) 0.999
Not available – 44 (10.3) 42 (10.9) 2 (4.7)
Blood parameters
Creatinine (mmol/L) 44–80 (f), 62–106 (m) 76.0 (17.0) 76.1 (17.2) 75.3 (15.2) 0.795
eGFR (mL/min/1.73 m2) – 96.6 (19.4) 96.5 (19.9) 97.1 (15.5) 0.854
Glucose (mmol/L) 3.9–5.6 5.4 (1.3) 5.4 (1.3) 5.5 (1.1) 0.699
HbA1c (%) 4.4–5.7 5.5 (0.7) 5.5 (0.7) 5.5 (0.7) 0.892
Cholesterol (mmol/L) <5.0 4.9 (1.2) 5.0 (1.2) 4.5 (0.9) 0.016
Calcium (mmol/L) 2.09–2.54 2.4 (0.1) 2.4 (0.1) 2.3 (0.1) 0.033
Phosphate (mmol/L) 0.87–1.45 1.0 (0.2) 1.0 (0.2) 1.0 (0.3) 0.898
25(OH) D3 (nmol/L) 75–140 53.7 (26.7) 53.1 (26.0) 57.8 (32.0) 0.286
1,25(OH)2 D3 (pmol/L) 47.7–190.3 103.5 (35.9) 103.3 (35.3) 105.2 (41.3) 0.752
PTH (ng/L) 15.0–65.0 43.9 (24.8) 44.6 (25.7) 38.1 (14.7) 0.105
Serum bicarbonate (mmol/L) 22.0–29.0 26.7 (2.7) 26.7 (2.8) 26.7 (2.5) 0.943
Potassium (mmol/L) 3.3–4.5 4.3 (1.8) 4.3 (1.9) 4.1 (0.5) 0.453
Chloride (mmol/L) 98–107 101.9 (2.8) 101.9 (2.8) 102.3 (2.6) 0.299
Sodium (mmol/L) 136–145 141.2 (2.4) 141.2 (2.4) 141.2 (2.1) 0.957
Anion gap (mmol/L) – 12.6 (2.6) 12.7 (2.6) 12.3 (2.6) 0.359
24-h urine collection parameters
Volume (mL) – 1778.8 (797.9) 1767.5 (790.3) 1878.1 (865.4) 0.395
pH – 6.0 (1.2) 6.0 (1.3) 5.9 (0.7) 0.339
Creatinine (mmol/24 h) 7.0–14.0 (f), 9.0–21.0 (m) 12.9 (5.6) 13.1 (5.8) 11.6 (3.5) 0.177
Sodium (mmol/24 h) 38.0–217.0 (f), 47.0–326.0 (m) 162.3 (79.7) 161.3 (75.3) 170.5 (111.6) 0.479
Potassium (mmol/24 h) 31.0–106.0 (f), 37.0–131.0 (m) 58.7 (23.7) 58.8 (24.4) 58.0 (17.6) 0.839
Calcium (mmol/24 h) <6.3 (f) , <7.5 (m) 5.6 (3.2) 5.8 (3.3) 4.7 (2.5) 0.039
Phosphate (mmol/24 h) 12.9–42.0 26.1 (10.4) 26.3 (10.6) 23.8 (8.4) 0.144
Magnesium (mmol/24 h) 3.0–5.0 3.9 (1.8) 4.0 (1.8) 3.4 (1.7) 0.071
Citrate (mmol/24 h) 1.0–6.5 2.7 (1.5) 2.8 (1.5) 2.4 (1.3) 0.108
Oxalate (mmol/24 h) <0.5 0.207 (0.166) 0.200 (0.122) 0.263 (0.374) 0.021
Uric acid (mmol/24 h) 1.2–5.9 3.1 (1.3) 3.1 (1.3) 2.9 (1.0) 0.266
Ammonium (mmol/24 h) 10.0–107.0 19.2 (10.5) 19.5 (10.7) 16.5 (8.2) 0.093
Age at first kidney stone (years) 36.6 (14.2) 36.6 (14.1) 36.6 (15.0) 0.989
Stone composition, n (%)
Calcium oxalate – 150 (43.2) 132 (44.5) 18 (36.0) 0.337
Apatite – 9 (2.6) 9 (3.0) 0 (0.0) 0.368
Uric acid – 7 (2.0) 6 (2.0) 1 (2.0) 0.999
Other – 4 (1.2) 3 (1.0) 1 (2.0) 0.465
Mixed – 177 (51.0) 147 (49.5) 30 (60.0) 0.222
Unknown – 595 526 69 0.250
Values are presented as mean (SD) unless stated otherwise. f, female; m, male.
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27.664.7 kg/m2 and diabetes mellitus type 2 was present in 7
(16.3%) patients, whereas diabetes mellitus type 1 was not pre-
sent in this group. Only 30.2% were recurrent stone formers,
and stone composition of potassium citrate-treated patients
consisted of mixed type (60.0%), pure calcium oxalate (36.0%),
uric acid (2.0%) and others (2.0%). In non-citrate-treated patients
calculi consisted of mixed type (49.5%), pure calcium oxalate
(44.5%), pure apatite (3.0%) and uric acid (2.0%). In this group,
1.0% of calculi were of other compositions and 41.7% of the
patients were recurrent stone formers.
At baseline, serum cholesterol and calcium levels were
markedly lower in citrate-treated patients. Also, urinary cal-
cium excretion (5.863.3 versus 4.76 2.5 mmol/24 h) was
lower in the potassium citrate group, whereas urinary oxa-
late excretion (0.260.1 versus 0.36 0.4 mmol/24 h) was
higher (Table 1). There were no further differences regarding
all other parameters at baseline between both patient
groups.
Impact of potassium citrate supplementation on 24-h
urine risk profile parameters
Blood and 24-h urinary parameters of all patients with or with-
out potassium citrate supplementation are presented in
Tables 2 and 3. Interestingly, parathyroid hormone (PTH) de-
clined significantly in all patients (C: 38.16 14.7 to
37.1614.8 ng/L, NC: 44.66 25.7 to 40.46 17.9 ng/L), whereas cal-
cidiol only increased in patients not treated with potassium cit-
rate (53.16 26.0 to 58.8630.0 nmol/L). No relevant changes were
found for all other blood parameters after potassium citrate
therapy.
As expected, both urinary citrate (Figure 2) and potassium
(Figure 3) excretion increased significantly (2.461.3 to
3.362.1 mmol/24 h and 58.0617.6 to 69.6629.1 mmol/24 h,
FIGURE 1: Frequency of urinary metabolic risk factors at baseline. Hypercalciuria
was most frequent followed by hypocitraturia, hyperuricosuria and
hyperoxaluria.
Table 2. Blood and 24-h urine parameters of patients with potassium citrate supplementation
Baseline 3 months
Parameters Value n Value n P-value
BMI (kg/m2) 27.6 (4.7) 40 27.8 (4.2) 8 0.522
Blood parameters
Creatinine (mmol/L) 75.3 (15.2) 43 77.5 (18.0) 43 0.154
eGFR (mL/min/1.73 m2) 97.1 (15.5) 43 97.0 (16.5) 43 0.932
Glucose (mmol/L) 5.5 (1.1) 39 5.4 (1.1) 39 0.321
HbA1c (%) 5.5 (0.7) 43 5.5 (1.0) 42 0.661
Cholesterol (mmol/L) 4.5 (0.9) 43 4.5 (1.0) 43 0.906
Calcium (mmol/L) 2.3 (0.1) 42 2.3 (0.2) 41 0.312
Phosphate (mmol/L) 1.0 (0.3) 43 1.1 (0.3) 43 0.311
25(OH) D3 (nmol/L) 57.8 (32.0) 43 58.3 (28.0) 43 0.887
1,25(OH)2 D3 (pmol/L) 105.2 (41.3) 42 101.2 (32.1) 42 0.516
PTH (ng/L) 38.1 (14.7) 43 37.1 (14.8) 43 <0.001
Serum bicarbonate (mmol/L) 26.7 (2.5) 41 27.4 (2.4) 39 0.148
Potassium (mmol/L) 4.1 (0.5) 43 4.2 (0.3) 43 0.104
Chloride (mmol/L) 102.3 (2.6) 43 102.7 (2.5) 43 0.536
Sodium 141.2 (2.1) 43 141.0 (2.1) 43 0.565
24-h urine collection parameters
Volume (mL) 1878.1 (865.4) 42 2076.4 (878.7) 42 0.056
pH 5.9 (0.7) 26 6.1 (0.6) 40 0.022
Creatinine (mmol/24 h) 11.6 (3.5) 42 12.74 (5.2) 42 0.126
Sodium (mmol/24 h) 170.5 (111.6) 42 169.0 (88.2) 42 0.919
Potassium (mmol/24 h) 58.0 (17.6) 42 69.6 (29.1) 42 0.015
Calcium (mmol/24 h) 4.7 (2.5) 42 5.0 (2.6) 42 0.307
Phosphate (mmol/24 h) 23.8 (8.4) 40 24.8 (10.6) 40 0.587
Magnesium (mmol/24 h) 3.4 (1.7) 42 4.3 (3.0) 42 0.016
Citrate (mmol/24 h) 2.4 (1.3) 42 3.3 (2.1) 42 <0.001
Oxalate (mmol/24 h) 0.263 (0.374) 41 0.272 (0.253) 42 0.688
Uric acid (mmol/24 h) 2.9 (1.0) 42 3.0 (1.3) 42 0.326
Ammonium (mmol/24 h) 16.5 (8.2) 49 16.2 (9.2) 37 0.575
Values are presented as mean (SD) unless stated otherwise.
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Table 3. Blood and 24-h urine parameters of patients without potassium citrate supplementation
Baseline 3 months
Parameters Value n Value n P-value
BMI (kg/m2) 26.5 (4.7) 336 26.8 (4.2) 59 0.261
Blood parameters
Creatinine (mmol/L) 76.1 (17.2) 351 76.8 (18.1) 200 0.837
eGFR (mL/min/1.73 m2) 96.5 (19.9) 349 95.8 (21.4) 198 0.932
Glucose (mmol/L) 5.4 (1.3) 308 5.4 (1.3) 178 0.890
HbA1c (%) 5.5 (0.7) 338 5.6 (2.3) 196 0.327
Cholesterol (mmol/L) 5.0 (1.2) 348 5.0 (1.1) 200 0.999
Calcium (mmol/L) 2.4 (0.1) 345 2.4 (0.1) 194 0.908
Phosphate (mmol/L) 1.0 (0.2) 344 1.0 (0.2) 193 0.740
25(OH) D3 (nmol/L) 53.1 (26.0) 342 58.8 (30.0) 197 0.025
1,25(OH)2 D3 (pmol/L) 103.3 (35.3) 341 106.7 (41.5) 191 0.696
PTH (ng/L) 44.6 (25.7) 337 40.4 (17.9) 194 <0.001
Serum bicarbonate (mmol/L) 26.7 (2.8) 281 27.0 (2.6) 170 0.450
Potassium (mmol/L) 4.3 (1.9) 350 4.2 (0.3) 199 0.927
Chloride (mmol/L) 101.9 (2.8) 350 100.2 (10.3) 198 0.028
Sodium 141.2 (2.4) 350 140.8 (3.0) 199 0.299
24-h urine collection parameters
Volume (mL) 1767.5 (790.3) 369 2131.5 (724.7) 171 <0.001
pH 6.0 (1.3) 249 6.0 (0.6) 135 0.707
Creatinine (mmol/24 h) 13.1 (5.8) 365 14.1 (18.5) 169 0.522
Sodium (mmol/24 h) 161.3 (75.3) 368 156.2 (70.3) 169 0.361
Potassium (mmol/24 h) 58.8 (24.4) 368 59.7 (23.5) 169 0.244
Calcium (mmol/24 h) 5.8 (3.3) 368 6.0 (3.3) 168 0.360
Phosphate (mmol/24 h) 26.3 (10.6) 332 26.5 (11.8) 145 0.903
Magnesium (mmol/24 h) 4.0 (1.8) 368 4.0 (1.7) 167 0.891
Citrate (mmol/24 h) 2.8 (1.5) 362 2.9 (1.4) 164 0.044
Oxalate (mmol/24 h) 0.200 (0.122) 364 0.229 (0.108) 166 <0.001
Uric acid (mmol/24 h) 3.1 (1.3) 368 3.0 (1.2) 169 0.619
Ammonium (mmol/24 h) 19.5 (10.7) 356 21.0 (12.2) 149 0.384
Values are presented as mean (SD) unless stated otherwise.
FIGURE 2: Plot of 24-h urinary citrate excretion at baseline and 3 months. Plot shows the mean 6 SD. (a) In Group C, 24-h citrate excretion increased significantly be-
tween baseline and 3 months. ***P<0.001. (b) In Group NC, 24-h citrate excretion increased significantly between baseline and 3 months. *P<0.05.
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respectively) after potassium citrate supplementation. In addi-
tion, a significant increase in urinary pH was detected (from
5.960.7 to 6.160.6; Figure 4), whereas urinary calcium excre-
tion (Figure 5) did not change after potassium citrate therapy.
In patients who were not receiving potassium citrate, both uri-
nary citrate excretion (from 2.861.5 to 2.96 1.4 mmol/24 h) and
24-h urine volume increased significantly (Figure 6).
We additionally performed between-group analyses to com-
pare the changes in blood and urinary parameters between
both groups. Notably, the mean change of citrate excretion was
significantly higher in patients who were treated with potas-
sium citrate (1.06 1.7 mmol/24 h) compared with the NC group
(0.26 1.3 mmol/24 h; Table 4). The comparison of urinary pH be-
tween both groups demonstrated a trend towards a higher
change in the citrate group when compared with the NC
group. Taken together, citrate supplementation resulted in a
beneficial change of urinary parameters in hypo- and
normocitraturic KSFs.
Hypocitraturia is associated with lower serum
bicarbonate levels in KSFs
Patients were divided into two groups according to urinary cit-
rate excretion (Table 5): Group 1, normocitraturic and Group 2,
hypocitraturic. A total of 78 patients (19.3%) presented with
hypocitraturia at baseline (Figure 1), of which 14 (17.9%) were
treated with potassium citrate. As expected, significantly more
hypocitraturic patients received potassium citrate therapy after
FIGURE 4: Plot of 24-h urine pH at baseline and 3 months. Plot shows the mean 6 SD. (a) In Group C, 24-h urine pH increased significantly between baseline and
3 months. *P<0.05. (b) In Group NC, 24-h urine pH did not show changes.
FIGURE 3: Plot of 24-h urinary potassium excretion at baseline and 3 months. Plot shows the mean 6 SD. (a) In Group C, 24-h potassium excretion increased signifi-
cantly between baseline and 3 months. *P<0.05. (b) In Group NC, 24-h potassium did not show changes.
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baseline (17.9% versus 8.6%). Inflammatory bowel disease (IBD)
showed a trend of greater prevalence in hypocitraturic patients
(P¼ 0.056), suggesting increased urinary citrate reabsorption in
response to enteric bicarbonate losses. Furthermore, serum bi-
carbonate levels were significantly lower in hypocitraturic
patients (25.86 3.2 versus 26.962.6 mmol/L), indicating renal
tubular acidosis or enteric bicarbonate loss as the potential un-
derlying cause. Serum calcium was significantly higher in nor-
mocitraturic patients (2.460.1 mmol/L) compared with
hypocitraturic patients (2.36 0.1 mmol/L), with no differences
found for 25-hydroxyvitamin D3, 1,25(OH)2 D3 and PTH.
At baseline, 24-h urine volume was markedly higher in nor-
mocitraturic patients compared with hypocitraturic patients
(1823.96 762.9 versus 1575.86912.8 mL/24 h). Interestingly,
urinary calcium (6.163.2 versus 3.962.8 mmol/24 h), potas-
sium (62.4623.2 versus 42.46 18.2 mmol/24 h), phosphate
(27.66 10.1 versus 19.769.1 mmol/24 h), uric acid (3.261.3
versus 2.360.9 mmol/24 h) and sodium (171.9681.1 versus
122.7661.3 mmol/24 h) were also significantly higher in nor-
mocitraturic patients at baseline (Table 5).
Citrate supplementation had no impact on fasting
glucose, HbA1c, cholesterol and BMI
Endogenous citrate has been reported to have a positive regulatory
effect on lipogenesis and a negative regulatory effect on glycolysis,
FIGURE 6: Plot of 24-h urine volume at baseline and 3 months. Plot shows the mean 6 SD. (a) In Group C, 24-h urine volume did not show changes. (b) In Group NC,
24-h urine volume increased significantly between baseline and 3 months. ***P< 0.001.
FIGURE 5: Plot of 24-h urinary calcium excretion at baseline and 3 months. Plot shows the mean 6 SD. (a) In Group C, 24-h urinary calcium excretion did not show
changes. (b) In Group NC, 24-h urinary calcium excretion did not show changes.
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but it is unknown if there is also an effect of oral citrate supple-
mentation on glucose and lipid parameters in KSFs. In our analysis,
no significant changes in fasting glucose (5.56 1.1 to
5.461.1 mmol/L), HbA1c (5.560.7 to 5.561.0%), cholesterol
(4.560.9 to 4.561.0 mmol/L) and BMI (27.664.7 to 27.864.2 kg/m2)
were found in potassium citrate–treated stone formers after
3 months (Figure 7 and Table 2). Similarly, fasting glucose, HbA1c,
cholesterol and BMI were unchanged after 3 months in stone for-
mers who were not receiving potassium citrate (Table 3).
Serum 1,25(OH)2 D3 levels were not associated with
urinary citrate excretion
The active form of vitamin D, 1,25(OH)2 D3, has been reported to
increase urinary citrate excretion [25]. We performed multiple
linear regression analyses to predict urinary citrate excretion
based on 1,25(OH)2 D3 (Model 1, Figure 8) and 1,25(OH)2 D3 and
estimated glomerular filtration rate (eGFR; Model 2). No signifi-
cant regression was found for either model.
DISCUSSION
We performed an analysis including 428 participants of the SKSC
to address the impact of citrate supplementation on urinary
parameters, glucose and lipid metabolism and association of
1,25(OH)2 D3 and urinary citrate excretion. To the best of our
knowledge, this is the first study investigating potential metabolic
side effects of potassium citrate metaphylaxis in this population.
At baseline, 19.3% of the cohort patients presented with
hypocitraturia. In addition to hypercalciuria, hypocitraturia has
been reported as the most common risk factor in KSFs [15–17,
Table 4. Mean change of blood and urine parameters of patients
with potassium citrate supplementation (Group C) compared with
patients without supplementation (Group NC)
Parameters Mean change C
Mean change
NC P-value
BMI (kg/m2) 0.6 (2.4) 0.2 (1.4) 0.695
Creatinine (mmol/L) 2.2 (9.8) 0.1 (6.9) 0.194
eGFR (mL/min/1.73 m2) 0.1 (7.1) 0.1 (9.8) 0.980
Glucose (mmol/L) 0.1 (0.6) 0.0 (1.3) 0.323
HbA1c (%) 0.0 (0.5) 0.2 (2.4) 0.282
Cholesterol (mmol/L) 0.0 (0.6) 0.0 (0.6) 0.914
Calcium (mmol/L) 0.0 (0.2) 0.0 (0.1) 0.341
Phosphate (mmol/L) 0.1 (6.4) 2.0 (7.5) 0.105
25(OH) D3 (nmol/L) 0.6 (26.1) 4.2 (25.5) 0.417
1,25(OH)2 D3 (pmol/L) 4.2 (41.0) 1.3 (44.6) 0.449
PTH (ng/L) 1.0 (10.5) 4.2 (22.8) 0.167
Serum bicarbonate (mmol/L) 0.7 (2.8) 0.2 (2.6) 0.308
Potassium (mmol/L) 0.1 (0.5) 0.0 (0.3) 0.109
Chloride (mmol/L) 0.3 (3.2) 1.7 (10.5) 0.029
Sodium 0.2 (2.6) 0.2 (3.3) 0.983
Volume (mL) 227.6 (740.9) 290.0 (716.0) 0.628
pH 0.2 (0.48) 0.0 (0.63) 0.066
Creatinine (mmol/24 h) 0.4 (3.4) 1.2 (8.3) 0.361
Sodium (mmol/24 h) 1.9 (122.0) 6.5 (91.4) 0.680
Potassium (mmol/24 h) 12.6 (31.7) 2.5 (27.5) 0.066
Calcium (mmol/24 h) 0.3 (2.1) 0.3 (3.5) 0.170
Phosphate (mmol/24 h) 1.0 (10.9) 0.1 (12.9) 0.598
Magnesium (mmol/24 h) 0.9 (2.3) 0.0 (1.8) 0.020
Citrate (mmol/24 h) 1.0 (1.7) 0.2 (1.3) 0.010
Oxalate (mmol/24 h) 0.013 (0.198) 0.041 (0.129) 0.385
Uric acid (mmol/24 h) 0.2 (1.3) 0.1 (1.5) 0.271
Ammonium (mmol/24 h) 0.0 (6.1) 1.0 (13.3) 0.539
Values are presented as mean (SD) unless stated otherwise.
Table 5. Baseline characteristics of normocitraturic versus
hypocitraturic KSFs
Parameters NormocitraturicHypocitraturic
P-
value
Patients, n (%) 326 (80.7) 78 (19.3) –
Age (years) 47.3 (13.7) 46.5 (15.8) 0.658
Gender (male), n (%) 232 (71.2) 53 (67.9) 0.673
BMI (kg/m2) 26.9 (4.7) 25.5 (5.1) 0.030
Received citrate therapy
after baseline, n (%)
28 (8.6) 14 (17.9) 0.026
Medical history, n (%)
Hypertension 62 (19.0) 20 (25.6) 0.296
Not available 29 (8.9) 5 (6.4)
Diabetes mellitus – – 0.489
Type 1 3 (0.9) 0 (0.0)
Type 2 31 (9.5) 10 (12.8)
Not available 26 (8.0) 6 (7.7)
IBD 10 (3.1) 7 (9.0) 0.056
Not available 32 (9.8) 4 (5.1)
Blood parameters
Creatinine (mmol/L) 76.3 (16.8) 76.0 (18.5) 0.895
eGFR (mL/min/1.73 m2) 96.5 (19.8) 96.2 (19.2) 0.896
Glucose (mmol/L) 5.5 (1.3) 5.3 (1.1) 0.208
HbA1c (%) 5.5 (0.7) 5.4 (0.7) 0.934
Cholesterol (mmol/L) 4.9 (1.1) 4.8 (1.2) 0.476
Calcium (mmol/L) 2.4 (0.1) 2.3 (0.1) 0.008
Phosphate (mmol/L) 1.0 (0.2) 1.0 (0.2) 0.342
25(OH) D3
(nmol/L)
53.9 (26.8) 53.8 (26.9) 0.985
1,25(OH)2 D3
(pmol/L)
102.4 (35.2) 106.2 (37.7) 0.409
PTH (ng/L) 44.8 (26.7) 40.3 (17.3) 0.169
Serum bicarbonate
(mmol/L)
26.9 (2.6) 25.8 (3.2) 0.003
Potassium (mmol/L) 4.4 (2.0) 4.1 (0.3) 0.395
Chloride (mmol/L)} 101.8 (2.7) 102.5 (2.9) 0.070
Sodium (mmol/L) 141.2 (2.4) 141.0 (2.2) 0.509
Anion gap (mmol/L) 12.5 (2.6) 13.0 (2.9) 0.233
24-h urine collection
parameters
Volume (mL) 1823.9 (762.9) 1575.8 (912.8) 0.014
pH 6.0 (0.6) 5.9 (0.6) 0.825
Creatinine (mmol/24 h) 13.4 (4.8) 10.3 (4.7) <0.001
Sodium (mmol/24 h) 171.9 (81.1) 122.7 (61.3) <0.001
Potassium (mmol/24 h) 62.4 (23.2) 42.4 (18.2) <0.001
Calcium (mmol/24 h) 6.1 (3.2) 3.9 (2.8) <0.001
Phosphate (mmol/24 h) 27.6 (10.1) 19.7 (9.1) <0.001
Magnesium (mmol/24 h) 2.6 (1.4) 2.5 (1.5) 0.617
Citrate (mmol/24 h) 3.2 (1.3) 0.9 (0.4) <0.001
Oxalate (mmol/24 h) 0.209 (0.122) 0.201 (0.285) 0.727
Uric acid (mmol/24 h) 3.2 (1.3) 2.3 (0.9) <0.001
Ammonium (mmol/24 h) 19.4 (8.6) 18.6 (16.4) 0.542
Age at first kidney stone (years) 36.8 (13.8) 36.4 (15.9) 0.859
Stone composition, n (%)
Calcium oxalate 113 (44.6) 27 (34.6) 0.173
Apatite 4 (1.6) 5 (6.4) 0.054
Uric acid 9 (3.5) 0 (0.0) 0.124
Other 5 (1.9) 1 (1.3) 0.999
Mixed 125 (48.4) 45 (57.7) 0.193
Unknown 462 111 0.196
Values are presented as mean (SD) unless stated otherwise.
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29]. Accordingly, hypercalciuria and hypocitraturia were highly
prevalent in our cohort. Potassium citrate was administered to
43 patients (10.0%), with only 14 patients (32.6%) presenting
hypocitraturic. However, potassium citrate has been recom-
mended not only for patients with hypocitraturia, but also with
hypercalciuria, complete or incomplete distal renal tubular aci-
dosis, chronic diarrheal states, uric acid or cystine stones and
osteopenia/osteoporosis [18, 30].
The recommended dose of citrate supplementation accord-
ing to the European Association of Urology is 14–36 mmol/day
(4500–11 600 mg/day) [31]. In our cohort, potassium citrate was
prescribed at a mean dosage of 38196 1796 mg/day, correspond-
ing to 12.56 5.9 mmol potassium citrate/day. There are several
possible explanations for the rather low and variable prescribed
dosages in this cohort. Although evaluation of the patients was
performed according to a highly standardized protocol, indica-
tion and type of therapy were the responsibility of the treating
physician. Thus we cannot exclude that some physicians pre-
scribed lower dosages, for instance, to avoid gastrointestinal
side effects or because patients declined to increase the dose of
potassium citrate.
Supplementation with potassium citrate resulted in a signifi-
cant increase of both urinary citrate and potassium excretion,
confirming patient adherence to therapy. These findings are very
important since compliance has been reported to be limited by
gastrointestinal side effects, unpleasant salty taste, costs and/or
high pill burden [32, 33]. We could further confirm adherence by
a parallel increase in urinary pH. All these findings have been
reported by other authors following citrate therapy in KSFs [18,
34, 35]. However, most studies have described a greater percent-
age increase of citrate, potassium or pH when compared with
our cohort. In addition, several studies have described a signifi-
cant decrease in urinary calcium excretion following citrate sup-
plementation [18, 34–36]. A retrospective study by Hermann et al.
[34] demonstrated that citrate therapy led to a significant in-
crease in urinary pH as well as urinary citrate and potassium ex-
cretion in normo- and hypocitraturic patients. Robinson et al. [35]
analysed the effect of citrate in hypocitraturic patients after 6
FIGURE 7: (a) HbA1c, (b) fasting glucose, (c) cholesterol and (d) BMI at baseline and 3 months of patients receiving potassium citrate therapy (Group C). Plot shows the
mean6 SD. No significant changes were observed.
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months and detected a significant increase of urinary pH, citrate
and potassium excretion. Both studies and another recent study
from Song et al. [18] additionally demonstrated that citrate ther-
apy also resulted in a significant decrease in urinary calcium. In
our study, we observed no significant changes of urinary calcium
after citrate therapy. Three different mechanisms have been dis-
cussed to decrease urinary calcium excretion by administration
of citrate [18]. First, therapy with potassium citrate results in sys-
temic alkalinization and thereby a reduction of bone turnover,
which could consequently lead to lower glomerular filtration of
calcium, resulting in lower urinary calcium levels. Second, citrate
binds calcium in the gastrointestinal tract, resulting in lower in-
testinal calcium reabsorption into blood and thus lower urinary
calcium excretion. Finally, the alkaline-sensitive TRPV5 channels
in the distal convoluted tubule seem to be more active at higher
urinary pH and thus enhance reabsorption of urinary calcium
from the tubular fluid [37].
However, in our study, PTH levels were significantly lower
after citrate supplementation. PTH, directly and indirectly, acti-
vates TRPV5 channels [38]. Thus a reduction in PTH, as has been
shown in our cohort, may lead to less TRPV5 activity and there-
fore less renal calcium uptake, providing a potential explana-
tion for the lack of change in urinary calcium excretion. In
addition, compared with the retrospective study of Song et al.
[18], urinary potassium excretion increased by 22% in our cohort
versus 56% in theirs. This indicates lower doses and/or less
compliance with potassium citrate therapy in our cohort,
diminishing the effect of citrate on urinary calcium excretion.
Lastly, hypocitraturic patients demonstrated significantly lower
urinary calcium and phosphate levels at baseline that may ex-
plain no further significant decline after potassium citrate treat-
ment in these patients. Taken together, in our study, we
demonstrated that potassium citrate supplementation resulted
in a beneficial change of urinary risk profile parameters by par-
ticularly increasing the anti-lithogenic factors in urine.
Endogenous citrate has been reported to be involved in sev-
eral metabolic pathways, including a positive regulatory effect
on lipogenesis and a negative regulatory effect on glycolysis
[22–24]. More precisely, citrate inhibits the downstream enzyme
phosphofructokinase 1, which converts fructose 6-phosphate
and adenosine triphosphate to fructose 1,6-bisphosphate and
adenosine diphosphate. By inhibiting this step, less acetyl-CoA
is produced from glucose, which may lead to less fatty acid and
cholesterol synthesis. In mice, a combined citrate and sucrose
diet has resulted in altered glucose metabolism, indicating insu-
lin resistance in these animals and no changes of lipid parame-
ters [23]. Notably, despite the widespread use of potassium
citrate, no data exist on the potential impact of citrate on glu-
cose or lipid metabolism in humans and, in particular, on KSFs.
Thus we used fasting glucose, HbA1c, cholesterol levels and BMI
as surrogate markers for glucose and lipid metabolism from
KSFs who were subjected to potassium citrate therapy. After
3 months of citrate supplementation, no changes in fasting glu-
cose, HbA1c, cholesterol levels or BMI were found in our study.
Higher serum 1,25(OH)2 D3 levels in stone formers are associ-
ated with higher urinary calcium and phosphate excretion and
consequently a greater risk of kidney stone formation [39, 40].
Thus we were interested to know whether there is an associa-
tion between 1,25(OH)2 D3 levels and urinary citrate excretion in
KSFs. In our analysis, no significant regression between calci-
triol and urinary citrate excretion was found.
We would like to acknowledge that our study has several
limitations. In this study, data collection was performed at
baseline and at 3 months because only at these time points was
sample size sufficient for statistical analysis. Thus we might
have missed effects that occur and may be detected only after a
longer treatment period. According to the nature of the study,
several biases may have been present, such as bias in indication
and dosage of potassium citrate therapy, as well as bias in diet
and adherence to physician’s recommendations (e.g. advice on
fluid or salt intake) and to potassium citrate therapy.
Furthermore, a substantial number of patients who were
treated with potassium citrate were normocitraturic and, im-
portantly, the majority of the hypocitraturic patients did not re-
ceive citrate supplementation. Moreover, additional medication
was not documented comprehensively in the patient data
forms. However, we could demonstrate a significant increase in
urinary potassium, citrate and pH, most probably excluding a
lack of patient adherence to citrate intake in our cohort.
Thus further randomized controlled trials with larger sample
sizes and a well-designed intervention are required to allow con-
firmation of our data and to fully elucidate the various effects of
potassium citrate on different metabolic pathways in KSFs.
CONCLUSION
In conclusion, potassium citrate supplementation resulted in a
beneficial change of the urinary risk profile by increasing anti-
lithogenic factors in urine. In addition, fasting glucose, HbA1c,
cholesterol levels and BMI were unaffected by potassium citrate
therapy after 3 months, suggesting that potassium citrate may
be safe and not associated with unfavourable metabolic side
effects. Lastly, there was no anti-lithogenic effect of calcitriol on
urinary risk profile of KSFs since 1,25(OH)2 D3 levels were not as-
sociated with urinary citrate excretion.
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